Biotech Values

[jq1234]

I take the contrarian view here. I think likely AZN seriously considered acquisition of AMRN. Uncertainty of NCE and valuation probably led to OMTH's Epanova. Epanova doesn't have much differentiation from Lovaza. I wonder whether Epanova could get mixed dyslipidemia indication Lovaza didn't. There is a market for prescription fish oil from big pharma, obviously at right valuation. Even though I had been negative on AMRN, I now see AMRN attractive down here.